Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Randomized Study of Xenical in Adolescents with Obesity and Metabolic Disorders
2016-001661-91Phase 3
- Sponsor
- Roche
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of orlistat in obesity, metabolic diseases, cardiac morbidity and 1 more (2 arms), sponsored by Roche. Primary endpoint: Change in total amount of adipose and muscular tissues.
02
Drugs
orlistat
03
Conditions
obesitymetabolic diseasescardiac morbiditytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001661-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001661-91.